JHP Pharmaceuticals has added a second product to an established multi-year contract with an undisclosed pharmaceutical company. JHP will be responsible for manufacturing and supply of an injectable anesthetic agent.
Stuart Hinchen president and CEO of JHP stated, “We are very pleased that JHP was chosen again by this well- established customer, as it speaks to their satisfaction with our work. We recently successfully completed an FDA (CBER) Pre-Approval Inspection in support of a biologic product launch for another long-term contract customer. JHP’s approach in meeting contract customer needs in a timely fashion creates an environment where customers are confident bringing additional manufacturing needs to us. Customers also rely on our extensive experience working with products throughout their life cycle which results in continuity of supply and program efficiencies.”
Hinchen noted, “JHP’s cGMP compliance record and established infrastructure combined with a broad and deep experience base have established a foundation that supports growth with both new and long-term customers.”
JHP’s Rochester, Michigan manufacturing site has a solid history of manufacturing a broad range of sterile product types including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics.